Bridgewater, NJ (USA), October 22, 2015 – Amneal Pharmaceuticals recently won the award for “Company of the Year, Americas” at the 2015 Global Generics and Biosimilars Awards held in Madrid, Spain. This is the second straight year Amneal Pharmaceuticals was recognized by Generics bulletin, a global newsletter for the generics and biosimilars industries. “Amneal prides itself in staying true to its core values: integrity, accountability, hard work, and collaboration,” said Chirag Patel, Amneal co-CEO and Chairman. “Winning this award is proof that acting on our values and executing our growth strategy has enabled us to continue to deliver on our promise of providing high-quality, affordable medicines for patients around the world.” Amneal Pharmaceuticals is now the 7th largest U.S. manufacturer of generic pharmaceuticals by prescriptions and the fastest-growing company among the top ten generics manufacturers. With annual U.S. sales reaching $1 billion, the company’s portfolio now counts more than 86 U.S. FDA-approved molecules with another 171 in development in addition to 107 pending approval. This product pipeline encompasses offerings across multiple therapeutic areas and virtually all dosage forms.
About Amneal Pharmaceuticals Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities—all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey Visit www.amneal.com
Amneal Pharmaceuticals LLC